PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: paclitaxel + carboplatin + bevacizumab
Drug: carboplatin + paclitaxel + bevacizumab + PF-3512676

First Posted Date: 2006-04-12

Last Posted Date: 2009-09-28

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT00313768

Locations: 🇺🇸
Pfizer Investigational Site, San Marcos, Texas, United States

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

Phase 2

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: CP-751,871
Drug: docetaxel
Drug: prednisone

First Posted Date: 2006-04-12

Last Posted Date: 2013-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 204

Registration Number: NCT00313781

Locations: 🇬🇧
Pfizer Investigational Site, Guildford, United Kingdom

Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers

Phase 2

Completed

Conditions: Foot Ulcer, Diabetic
Diabetes Complications

First Posted Date: 2006-04-10

Last Posted Date: 2012-06-01

Lead Sponsor: Pfizer

Target Recruit Count: 322

Registration Number: NCT00312364

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
UCSD Wound Treatment and Research Center, San Diego, California, United States
🇺🇸
Institute for Advanced Wound Care, Montgomery, Alabama, United States

and more 60 locations

Thorough QT Study of Nelfinavir

Phase 4

Completed

Conditions: Healthy Volunteers

First Posted Date: 2006-04-07

Last Posted Date: 2009-04-10

Lead Sponsor: Pfizer

Target Recruit Count: 68

Registration Number: NCT00312182

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

Phase 3

Terminated

Conditions: Atherosclerosis
Kidney Failure

Interventions: Drug: tacrolimus
Drug: sirolimus
Drug: mycophenolate mofetil
Drug: prednisone

First Posted Date: 2006-04-05

Last Posted Date: 2013-09-23

Lead Sponsor: Pfizer

Target Recruit Count: 72

Registration Number: NCT00311311

Locations: 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada

A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency

Phase 2

Terminated

Conditions: Growth Hormone Deficiency

First Posted Date: 2006-03-29

Last Posted Date: 2011-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 136

Registration Number: NCT00308464

Locations: 🇬🇧
Pfizer Investigational Site, Oxford, United Kingdom

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

Phase 2

Completed

Conditions: Venous Thrombosis

First Posted Date: 2006-03-23

Last Posted Date: 2007-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 1225

Registration Number: NCT00306254

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure

Phase 2

Completed

Conditions: Diastolic Heart Failure

Interventions: Drug: Placebo
Drug: Sitexsentin sodium

First Posted Date: 2006-03-17

Last Posted Date: 2023-01-04

Lead Sponsor: Pfizer

Target Recruit Count: 200

Registration Number: NCT00303498

Locations: 🇺🇸
Massachusetts General Hospital Pulmonary and Critical Care Unit, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States

and more 48 locations

Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy

Completed

Conditions: Arthritis, Psoriatic, Psoriasis

First Posted Date: 2006-03-15

Last Posted Date: 2012-07-30

Lead Sponsor: Pfizer

Target Recruit Count: 107

Registration Number: NCT00303186

Locations: 🇮🇹
Pfizer Investigational Site, Roma, Italy

To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days

Phase 4

Completed

Conditions: Infections, Fungal

Interventions: Drug: voriconazole

First Posted Date: 2006-03-09

Last Posted Date: 2009-10-14

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00300677

Locations: 🇺🇸
Pfizer Investigational Site, Belmont, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy